Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

7.915 +0.395 (+5.25%)
Streaming Delayed Price Updated: 3:31 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptive Biotechnologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
What To Know About Piper Sandler's Upgrade of Adaptive Biotechnologies
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
Via Benzinga
Nike, FedEx And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Looking Into Adaptive Biotechnologies's Return On Capital Employed
Via Benzinga
Expert Ratings for Adaptive Biotechnologies
Adaptive Biotechnologies (NASDAQ:ADPT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed
  
Via Benzinga
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Clocks 26% Jump In Q4 Revenues
Adaptive Biotechnologies Corp (NASDAQ: ADPT)  
Via Benzinga
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results
From Adaptive Biotechnologies
Via GlobeNewswire
5 Top Stocks Cathie Wood Is Buying This Week
Cathie Wood just lauded Elon Musk's acquisition of Twitter, believing the platform will become a "super-app." Here are her top five buys. 
Via InvestorPlace
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
General Electric To Surge Around 27%? Plus This Analyst Predicts $44 For General Motors
  RBC Capital raised the price target on General Electric Company (NYSE: GE) from $81 to $93. General Electric shares fell 0.5% to close at $73.00 on Tuesday. 
Via Benzinga
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
Integration with the most widely used comprehensive electronic health record will expand clinician and patient access to clonoSEQ 
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022
From Adaptive Biotechnologies
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Adaptive Biotechnologies: Q2 Earnings Insights
Adaptive Biotechnologies (NASDAQ:ADPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Outlook For Adaptive Biotechnologies
Adaptive Biotechnologies (NASDAQ:ADPT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Why Adaptive Biotechnologies Shares Are Rising
Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares are trading higher by 12.58% to $7.25 after the company launched T-Detect Lyme, to help diagnose early lyme disease. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
Via Benzinga
Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed
Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $38.62 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 2.35%, resulting in a loss of $62.80... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) shares rose 78.8% to $3.04 during Wednesday's pre-market session. The market value of their outstanding shares is at $19.2... 
Via Benzinga
Adaptive Biotechnologies To Lay Off ~12% Of Its Workforce, Names Tycho Peterson As CFO
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) will be organized around two distinct business areas - Minimal Residual Disease (MRD) and Immune Medicine. Adaptive's... 
Via Benzinga
Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed
Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $37.93 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 9.57%, resulting in a loss of $61.36... 
Via Benzinga
Recap: Adaptive Biotechnologies Q4 Earnings
Adaptive Biotechnologies (NASDAQ:ADPT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.